(Q46742608)

24 December 2017

title

Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? (English)

1 reference

24 December 2017

0 references

1 reference

cytomegaloviral disease

1 reference

A Jain

1

1 reference

24 December 2017

M Orloff

2

1 reference

24 December 2017

R Kashyap

3

1 reference

24 December 2017

K Lansing

4

1 reference

24 December 2017

R Betts

5

1 reference

24 December 2017

R Mohanka

6

1 reference

24 December 2017

M Menegus

7

1 reference

24 December 2017

C Ryan

8

1 reference

24 December 2017

A Bozorgzadeh

9

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

24 December 2017

Transplantation Proceedings

published in

1 reference

24 December 2017

volume

37

1 reference

24 December 2017

issue

7

1 reference

24 December 2017

page(s)

3182-3186

1 reference

24 December 2017

CMV infection of transplant recipients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Cytomegalovirus disease following liver transplantation: an analysis of prophylaxis strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Pharmacokinetics of valganciclovir and ganciclovir in renal impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2005.07.032

10.1016/J.TRANSPROCEED.2005.07.032

7 January 2021

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017